Cytosorbents (CTSO) Other Operating Expenses (2010 - 2026)

Cytosorbents' Other Operating Expenses history runs 17 years deep, the most recent figure standing at -$6.6 million for Q1 2026.

• Quarterly Other Operating Expenses rose 5.12% year-over-year to -$6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 118.04% YoY) and the FY2025 annual result came in at $2.1 million, up 109.11% from the prior year.
• Other Operating Expenses was -$6.6 million for Q1 2026 at Cytosorbents, down from $22.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $22.5 million in Q4 2025 and bottomed at -$6.9 million in Q1 2024.
• A 5-year average of -$1.4 million and a median of -$3.4 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2024 — Other Operating Expenses plunged 1276.29% — and 2025, when it jumped 691.04%.
• Cytosorbents' Other Operating Expenses stood at $758569.0 in 2022, then slumped by 548.51% to -$3.4 million in 2023, then decreased by 12.07% to -$3.8 million in 2024, then soared by 691.04% to $22.5 million in 2025, then slumped by 129.09% to -$6.6 million in 2026.
• Business Quant data shows CTSO's Other Operating Expenses at -$6.6 million in Q1 2026, $22.5 million in Q4 2025, and -$6.0 million in Q3 2025.